Trade Ideas November 16, 2026 03:18 PM

Buy the International Rollout Dip: Hims & Hers at a Tactical Entry

Revenue growth remains intact; international expansion and new product launches can re-accelerate margins—trade plan built for a mid-term recovery.

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
HIMS

Hims & Hers (HIMS) has been punished after Q3 results and weaker guidance, but the combination of raised international targets, a partnership with Eli Lilly, and planned product launches creates a clear path to revenue and subscriber recovery. This trade idea is a tactical long on a mid-term horizon to capture a rebound as management re-prioritizes profitable branded launches outside the U.S.

Buy the International Rollout Dip: Hims & Hers at a Tactical Entry
HIMS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Q3 revenue $890.4M, up ~49% YoY; gross margin compressed to 57% from 74%.
  • Management raised international revenue outlook to at least $650M, making geographic expansion a core near-term catalyst.
  • Partnership with Eli Lilly and new Peptides+ category create potential revenue and ARPU upside, but initially pressure margins.
  • Tactical long entry $18.50, target $28.00, stop $15.00, mid-term horizon (45 trading days).

Hook & thesis

Hims & Hers (HIMS) pulled back sharply after Q3 and weak Q4 guidance, but the core business still prints healthy growth and management is doubling down on international expansion as a top-line lever. Revenue is scaling rapidly, last quarter came in near $890 million, and management now expects at least $650 million in international revenue going forward. That combination—fast top-line growth plus a pivot to higher-growth geographies—makes HIMS a tactical long from current levels for traders willing to accept margin volatility in the near term.

My trade thesis: buy near-term weakness to position for a mid-term rebound driven by (1) international revenue ramp, (2) product category expansion (Peptides+ and other branded offerings), and (3) the recently announced Lilly partnership for approved weight-loss drugs. Entry is set below the market to account for continued volatility; targets assume a partial recovery toward historical multiple expansion once margins stabilize.

What Hims & Hers does and why the market should care

Hims & Hers operates a direct-to-consumer telehealth platform connecting patients to care across sexual health, dermatology, primary care and weight-loss therapies. The value proposition is convenience plus a vertically integrated fulfillment and care model. The market cares because digital-first, low-friction access to chronic-care treatments is still under-penetrated globally; management is positioning HIMS to capture share both at home and abroad.

Fundamental drivers

  • Scale of revenue growth: Q3 revenue was $890.4 million, up roughly 49% year-over-year. Rapid revenue growth gives the company flexibility to invest internationally and absorb short-term margin pressure.
  • International expansion: management raised international revenue outlook to at least $650 million, signaling that management expects overseas growth to be a material driver of 2027 revenue.
  • New product mix & partnerships: HIMS announced a partnership with Eli Lilly to distribute FDA-approved weight-loss drugs and is launching a Peptides+ category. These moves increase addressable market and could lift average revenue per user, but the immediate impact is diluted gross margin because branded weight-loss products carry lower initial margins.

The numbers you need to know

  • Q3 revenue: $890.37 million (up ~48.7% YoY).
  • Q3 EPS: $0.03, meaningfully below estimates; management lowered full-year adjusted EBITDA guidance to $257–$277 million.
  • Gross margin compressed to 57% from 74% year-over-year, reflecting higher penetration of lower-margin weight-loss treatments and international sales.
  • Subscribers: sequential decline of 100,000 to 2.8 million, a read that management attributes to a deliberate U.S. marketing reset ahead of new branded treatments.
  • Market cap: roughly $4.37 billion and current price is $18.64. 52-week range is $13.74 - $40.99.
  • Valuation context: price-to-sales sits around ~1.8x and the company remains unprofitable on a GAAP basis (negative PE), but guidance for adjusted EBITDA of $257–$277M provides a forward profitability benchmark to watch.

Technical & sentiment backdrop

The stock has been under pressure: RSI sits near 31, moving averages are well above the current price (10-day SMA ~$22.34; 50-day SMA ~$27.43), and short interest remains significant (short interest in the 50M+ shares range). That combination often amplifies downside in the near term but also increases the upside for a tactical rebound when a visible catalyst appears.

Valuation framing

At a market cap near $4.37B and trailing multiples around 1.8x sales, HIMS is priced for a mix: continued growth but ongoing margin pressure. Historically, the stock traded at substantially higher multiples when gross margins were near the mid-70s and subscriber growth was steadier. The current multiple implies the market is discounting persistent margin compression and slower-than-expected monetization of new categories. If management can show sequential margin recovery and subscriber stabilization over the next two quarters, a re-rating back toward historical sales multiples is plausible.

Catalysts to watch (2-5)

  • International revenue execution: confirmation that international revenue hits or exceeds the raised outlook (~$650M) will prove the thesis that geographic diversification can offset U.S. growth resets.
  • Peptides+ and branded launches: patient adoption rates and gross margin contribution data from the new categories will determine whether top-line growth can translate to margin recovery.
  • Lilly partnership traction: prescription volume and patient conversion for Zepbound/Foundayo through HIMS' platform will be a near-term growth lever and a signal of monetization capability in specialty therapies.
  • Subscriber stabilization: reversal of the sequential subscriber decline (the 100k drop) would be an important behavioral signal that marketing and product changes are resonating.

Trade Plan (actionable)

Direction: Long

Entry price: $18.50

Target price: $28.00

Stop loss: $15.00

Horizon: mid term (45 trading days) with the possibility to hold into long term (180 trading days) if early catalysts confirm continued international momentum and product traction.

Rationale: enter slightly below the current market price to account for near-term volatility. A target of $28 assumes partial multiple restoration as margins stabilize and revenue guidance is validated; $28 is well below the prior 52-week high of $40.99, so this trade aims for recovery rather than a full re-rating. Stop loss at $15 limits downside in the event the international roll-out or branded category launches disappoint materially.

Risks & counterarguments

  • Margin risk: Gross margins compressed from 74% to 57% due to lower-margin weight-loss sales and international mix. If the new product mix stays lower-margin, profitability could remain impaired and shares could re-price lower.
  • Subscriber attrition: A 100,000 sequential subscriber decline is non-trivial. If subscriber count continues to fall, revenue growth could slow despite international expansion and branded product launches.
  • Execution risk on international ramp: Scaling healthcare in new geographies requires regulatory, supply-chain and marketing investments. Execution missteps or slower adoption overseas would undercut the thesis that international is a near-term growth engine.
  • Competition & pricing pressure: The telehealth space is crowded; partnerships (like Lilly) help, but competitors can undercut price or roll out similar offerings, pressuring revenue per user and margins.
  • Valuation re-rating risk: The market may demand sustained margin recovery, not just top-line growth, before re-rating the stock; that could push the timeline for upside beyond the planned horizon.

Counterargument: One reasonable counterargument is that management is already burning cash to chase scale—international expansion plus low-margin weight-loss fulfillment could be a value-destructive pivot. If branded therapies fail to drive higher CLTV or if international customer economics are weak, the correct stance could be to avoid the name until margins prove durable. That’s why the trade uses a tight stop and a mid-term horizon: to capture upside if catalysts show early promise while limiting exposure if evidence contradicts the thesis.

What will change my mind

  • I would abandon the long stance if international revenue guidance is cut or if management reports a second sequential subscriber decline beyond the marketing reset explanation.
  • I would also change my view if gross margins fail to show at least a stabilizing trend after the initial Peptides+ launches and Lilly partnership rollout; persistent margin decline would require reassessing valuation and time horizon.

Conclusion

Hims & Hers offers a clear asymmetric trade for traders who accept near-term margin noise in exchange for a path to re-rating: strong revenue growth, a committed international push and new product categories that broaden the addressable market. The technical setup and elevated short interest amplify volatility, creating opportunities for tactical entry. This trade plan goes long at $18.50, targets $28.00 over a mid-term (45 trading days) horizon with a stop at $15.00. If international execution and product adoption show early traction, the stock could re-price materially higher; if not, the stop protects capital.

Risks

  • Sustained margin compression from higher mix of lower-margin weight-loss products and international sales.
  • Continued subscriber attrition that offsets new product and international revenue gains.
  • Execution risk in international markets: regulatory, supply-chain and go-to-market missteps.
  • Competitive pressure and pricing dynamics in telehealth could limit ARPU and prolong the re-rating timeline.

More from Trade Ideas

Allegiant Travel: Earnings Beat, Bank of America Deal, and a Real Shot at a Durable Turnaround Nov 16, 2026 Upgrade: Buy Candel Therapeutics After the Prostate Filing Slip — Risk-Adjusted Long Nov 16, 2026 SanDisk Setup: A Clear Entry for a Cycle-Driven Rally Nov 16, 2026 SMCI: $19.9B Quarter and Legal De‑Risking — Why a Single‑Digit Multiple Looks Mistaken Nov 16, 2026 M-tron Industries: Upgrading to a Buy as Growth Visibility and Margins Improve Nov 16, 2026